Price of XL-184(Cabozantinib)
We offer a substantial discount on larger orders,
please inquire via firstname.lastname@example.org
or Fax: 1-201-884-1288(USA Fax#)
We match the lowest price on market.
XL184 is an orally bioactive, multitargeted inhibitor of tumor growth, metastasis and angiogenesis, simultaneously targeting c-MET, RET and VEGFR2 with IC50s at low nM.
Technical DataFormula: C28H24FN3O5.C4H6O5
Solubility : DMSO
Storage Conditions :Room temperature, or -20ºC for 2 year.
XL-184(Cabozantinib) MSDS XL-184 CoA
Reference[CITATION] A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid ˇ
R Salgia, S Sherman, DS Hong, CS Ng, J Fryeˇ - J Clin Oncol, 2008
[PDF] Phase 2 study of XL184 (BMS-907351), an inhibitor of MET, VEGFR2, and RET in patients with progressive glioblastoma
P Wen, M Prados, D Schiff, D Reardonˇ - J Clin Oncol, 2010 - exelixis.com
XL184 (BMS-907351) is being co-developed by Exelixis and Bristol-Myers Squibb ... VEGF and HGF have been implicated as major paracrine ... However, selective inhibition of VEGF signaling has been ... XL184 simultaneously inhibits VEGF and MET pathways,